Literature DB >> 21782056

Histopathology of mantle cell lymphoma.

Wolfram Klapper1.   

Abstract

Mantle cell lymphoma (MCL) is a relatively rare lymphoma, accounting for less than 10% only of all lymphomas. Its morphology is quite homogeneous, but it varies strikingly in about 10% of the cases, making the diagnosis of MCL challenging for histopathologists. The definition of the disease was greatly influenced by the discovery of the translocation t(11;14)(q13,q32), which juxtaposes the cyclin D1 and the immunoglobulin heavy chain genes and is present in the vast majority of MCL cases. The introduction of monoclonal antibodies for the detection of cyclin D1 expression into the diagnostic procedure substantially improved the reproducibility and reliability of the pathological diagnosis. However, new challenges for histopathologists have arisen over the last years, among which are the detection of cyclin D1-negative MCL cases and clinically relevant prognostic subgroups.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21782056     DOI: 10.1053/j.seminhematol.2011.03.006

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  11 in total

Review 1.  [Differential diagnosis of lymphoid infiltrates in the central nervous system: experience of the Network Lymphomas and Lymphomatoid Lesions in the Nervous System].

Authors:  W Brück; A Brunn; W Klapper; T Kuhlmann; I Metz; W Paulus; M Deckert
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

Review 2.  Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.

Authors:  Bijal D Shah; Peter Martin; Eduardo M Sotomayor
Journal:  Cancer Control       Date:  2012-07       Impact factor: 3.302

3.  Prognostic value and computer image analysis of p53 in mantle cell lymphoma.

Authors:  Yue-Hua Zhang; Li-Min Gao; Xiao-Yu Xiang; Wen-Yan Zhang; Wei-Ping Liu
Journal:  Ann Hematol       Date:  2022-08-03       Impact factor: 4.030

Review 4.  Blastoid Mantle Cell Lymphoma of the Palate: Report of a Rare Aggressive Entity and Review of the Literature.

Authors:  Maria Georgaki; Vasileios Ionas Theofilou; Efstathios Pettas; Evangelia Piperi; Eleana Stoufi; Panayiotis Panayiotidis; Nikolaos G Nikitakis
Journal:  Head Neck Pathol       Date:  2021-10-30

5.  t(11;14)-positive mantle cell lymphomas lacking cyclin D1 (CCND1) immunostaining because of a CCND1 mutation or exclusive expression of the CCND1b isoform.

Authors:  Ingram Iaccarino; Lamis Afify; Sietse M Aukema; Katharina Reddemann; Philipp Schütt; Martin Flür; Wolfram Klapper
Journal:  Haematologica       Date:  2018-05-17       Impact factor: 9.941

Review 6.  Male breast cancer and mantle cell lymphoma in a single patient: A case report and literature review.

Authors:  Jun Liu; Hongquan Wei; Keqing Zhu; Liqin Lai; Xiaoyu Han; Yue Yang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

7.  High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis.

Authors:  Philippa Li; Ji Yuan; Fahad Shabbir Ahmed; Austin McHenry; Kai Fu; Guohua Yu; Hongxia Cheng; Mina L Xu; David L Rimm; Zenggang Pan
Journal:  Front Oncol       Date:  2021-08-30       Impact factor: 6.244

8.  Rituximab-Induced Splenic Rupture and Cytokine Release.

Authors:  Ranjit Nair; Shereen Gheith; Nicholas Lamparella
Journal:  Am J Case Rep       Date:  2016-03-14

9.  Mantle Cell Lymphoma of the Palatine Tonsil: A Rare Case Report.

Authors:  Ranjitha Rao; Deviprasad Dosemane; Bhagyashree Jaipuria; Debarshi Saha; Manisha Narayan; Kanishka S Rao
Journal:  Iran J Otorhinolaryngol       Date:  2018-09

10.  Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma.

Authors:  A Barreca; C Martinengo; L Annaratone; L Righi; A Chiappella; M Ladetto; A Demurtas; L Chiusa; A Stacchini; N Crosetto; A van Oudenaarden; R Chiarle
Journal:  Blood Cancer J       Date:  2014-10-10       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.